Canrenoate
Back to searchMolecule Structure
Scientific Name
Canrenoate
Description of the Drug
Canrenoic acid is an aldosterone antagonist used in primary hyperaldosteronism and other disorders related to aberrant aldosterone levels.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB09015
http://www.drugbank.ca/drugs/DB09015
Brand Name(s)
Not Available
Company Owner(s)
Not Available
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Mineralocorticoid receptor | SINGLE PROTEIN | ANTAGONIST | CHEMBL1994 |
Clinical Trial(s)
Unichem Links
| Atlas | canrenoate | ||
| SureChEMBL | SCHEMBL636758 | ||
| DrugBank | DB09015 | ||
| PubChem: Thomson Pharma | 15076866 | ||
| PubChem | 656615 | ||
| LINCS | LSM-3029 | ||
| Nikkaji | J8.683E | ||
| EPA CompTox Dashboard | DTXSID5022726 | ||
| LipidMaps | LMST02030154 | ||
| DrugCentral | 477 | ||
| rxnorm | CANRENOATE POTASSIUM | CANRENOIC ACID | CANRENOATE |
| ChEBI | 50156 | ||
| ZINC | ZINC000003938750 |
